Prostate cancer therapy using immune checkpoint molecules to target recombinant dendritic cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prostate cancer therapy using immune checkpoint molecules to target recombinant dendritic cells

Published:2024 Issue:3 Volume:65 Page:300
ISSN:2466-0493
Container-title:Investigative and Clinical Urology
language:en
Short-container-title:Investig Clin Urol

Author:

Choi Se Young¹^ORCID,Kim Yunlim²³^ORCID,Lim Bumjin³^ORCID,Wee Chung Beum¹^ORCID,Chang In Ho¹^ORCID,Kim Choung-Soo⁴^ORCID

Affiliation:

1. Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.

2. Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea.

3. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

4. Department of Urology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea.

Funder

National Research Foundation of Korea

Publisher

XMLink

Link

https://icurology.org/pdf/10.4111/icu.20230348

Reference30 articles.

1. Cancer statistics, 2022

2. The treatment landscape of metastatic prostate cancer

3. Cancer immunotherapies, their safety and toxicity

4. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

5. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP